399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| id |
doaj-115fbf3202dd41a198c2223d3da6fcbc |
|---|---|
| record_format |
Article |
| spelling |
doaj-115fbf3202dd41a198c2223d3da6fcbc2020-12-11T10:01:52ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0399399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trialDean Harris0Daniel Brungs1Rahul Ladwah2Andrew Mant3Margaret McGrath4Andrea Tazbirkova5Andrey Akopov6Natalia Fadeeva7Boris Kasparov8Nadezhda Kovalenko9Vadim Kozlov10Fedor Moiseenko11Vasiliy Oschepkov12Piotr Koralewski13Dariusz Kowalski14Iwona Lugowska15Chaiyut Charoentumn16Arunee Dechaphunkul17Virote Sriuranpong18James Oliviero19Philip Clingan201Christchurch Hospital, Christchurch, New Zealand2Southern Medical Day Care Centre, Wollongong, Australia3Princess Alexandra Hospital, Woolloongabba, Australia4Eastern Health, Box Hill, Australia5Greenslopes Private Hospital, Greenslopes, Australia6Pindara Private Hospital, Benowa, Australia7First St. Petersburg State Med Univ, Saint-Petersburg, Russian Federation8Chelyabinsk Reg Clinical Oncology Center, Chelyabinsk, Russian Federation9NMRC of Oncology n.a. N.N. Petrov, Saint-Petersburg, Russian Federation10Volgograd Reg Clinical Onc Dispensary, Volgograd, Russian Federation11Novosibirsk Reg Clinical Onc Dispensary, Novosibirsk, Russian Federation12St. Petersburg Clin Res and Practical Ct, Saint-Petersburg, Russian Federation13Multidisciplinary Clin Med Ctr, Tyumen, Russian Federation14Szpital Specjalistyczny Ludwika Rydygier, Kraków, Poland15National Research Institute of Oncology, Warsaw, Poland15National Research Institute of Oncology, Warsaw, Poland16Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand17Prince of Songkla University, Songkhla, Thailand18King Chulalongkorn Memorial Hospital, Bangkok, Thailand19Checkpoint Therapeutics, New York, NY, USA2Southern Medical Day Care Centre, Wollongong, Australia |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Dean Harris Daniel Brungs Rahul Ladwah Andrew Mant Margaret McGrath Andrea Tazbirkova Andrey Akopov Natalia Fadeeva Boris Kasparov Nadezhda Kovalenko Vadim Kozlov Fedor Moiseenko Vasiliy Oschepkov Piotr Koralewski Dariusz Kowalski Iwona Lugowska Chaiyut Charoentumn Arunee Dechaphunkul Virote Sriuranpong James Oliviero Philip Clingan |
| spellingShingle |
Dean Harris Daniel Brungs Rahul Ladwah Andrew Mant Margaret McGrath Andrea Tazbirkova Andrey Akopov Natalia Fadeeva Boris Kasparov Nadezhda Kovalenko Vadim Kozlov Fedor Moiseenko Vasiliy Oschepkov Piotr Koralewski Dariusz Kowalski Iwona Lugowska Chaiyut Charoentumn Arunee Dechaphunkul Virote Sriuranpong James Oliviero Philip Clingan 399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial Journal for ImmunoTherapy of Cancer |
| author_facet |
Dean Harris Daniel Brungs Rahul Ladwah Andrew Mant Margaret McGrath Andrea Tazbirkova Andrey Akopov Natalia Fadeeva Boris Kasparov Nadezhda Kovalenko Vadim Kozlov Fedor Moiseenko Vasiliy Oschepkov Piotr Koralewski Dariusz Kowalski Iwona Lugowska Chaiyut Charoentumn Arunee Dechaphunkul Virote Sriuranpong James Oliviero Philip Clingan |
| author_sort |
Dean Harris |
| title |
399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial |
| title_short |
399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial |
| title_full |
399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial |
| title_fullStr |
399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial |
| title_full_unstemmed |
399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial |
| title_sort |
399 cosibelimab, an anti-pd-l1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial |
| publisher |
BMJ Publishing Group |
| series |
Journal for ImmunoTherapy of Cancer |
| issn |
2051-1426 |
| publishDate |
2020-11-01 |
| work_keys_str_mv |
AT deanharris 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT danielbrungs 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT rahulladwah 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT andrewmant 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT margaretmcgrath 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT andreatazbirkova 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT andreyakopov 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT nataliafadeeva 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT boriskasparov 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT nadezhdakovalenko 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT vadimkozlov 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT fedormoiseenko 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT vasiliyoschepkov 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT piotrkoralewski 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT dariuszkowalski 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT iwonalugowska 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT chaiyutcharoentumn 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT aruneedechaphunkul 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT virotesriuranpong 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT jamesoliviero 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial AT philipclingan 399cosibelimabanantipdl1antibodypreliminarysafetyandefficacyresultsfromaglobalmulticohortphase1clinicaltrial |
| _version_ |
1724386528661078016 |